UBS maintains Johnson & Johnson stock buy rating and $180 target

On Wednesday, UBS analyst Danielle Antalffy maintained a Buy rating with a $180.00 price target on Johnson & Johnson shares (NYSE:JNJ). Antalffy’s endorsement of the healthcare giant’s stock comes amid her positive outlook on the company’s underlying fundamentals. She highlighted two main pillars supporting this perspective: the robust sales growth of key innovative medicines and the resilience of Johnson & Johnson’s MedTech business.

Antalffy pointed out that the continued strong performance of Johnson & Johnson’s innovative medicines is expected to counterbalance the anticipated decline in sales of STELARA, a key product in their portfolio. She also noted the strategic acquisitions of ABMD and SWAV as significant contributors to growth, especially in segments facing headwinds, such as Orthopedics.

Johnson & Johnson’s diversified portfolio was emphasized as a core strength, particularly valuable in the current volatile market climate where the near-term macroeconomic environment remains uncertain. Antalffy acknowledged that the company’s shares had modestly underperformed up to today, potentially due to concerns about the anticipated $400 million tariff impact in 2025.

The first quarter of 2025 was cited by Antalffy as a further demonstration of Johnson & Johnson’s robust portfolio. Despite the challenges posed by the market and the looming tariff impact, the company’s performance was seen as a testament to its solid foundation and strategic growth initiatives.

Johnson & Johnson’s stock rating and price target affirmation by UBS reflect confidence in the company’s ability to navigate through market uncertainties and sustain growth through its innovative medicines and MedTech business strategies.

In other recent news, Johnson & Johnson reported its Q1 2025 earnings, surpassing Wall Street expectations. The company posted an adjusted EPS of $2.77, exceeding the forecast of $2.58, and reported revenue of $21.9 billion, surpassing the anticipated $21.57 billion. The earnings report highlighted a 4.2% increase in worldwide sales compared to the previous year, with significant growth in key product lines like DARZALEX and TREMFYA. Additionally, Johnson & Johnson announced the completion of its acquisition of Intra Cellular Therapies, enhancing its portfolio in central nervous system disorders. The company plans to invest over $55 billion in U.S. manufacturing, R&D, and technology over the next four years, marking a 25% increase from previous investments. Despite these positive developments, Johnson & Johnson’s stock experienced a slight dip in pre-market trading. Analyst firms have noted the company’s resilience, with expectations for continued growth driven by pipeline advancements and expected approvals in multiple therapeutic areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.